PHF21A

Across TCGA pan-cancer cohorts, PHF21A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PHF21A data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PHF21A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PHF21A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and ESCA are the cancer types where PHF21A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.069	0.688	<.001	18	view →
UCEC	DFS	Median	II,III,IV	0.925	0.436	.020	18	view →
ESCA	OS	Median	All	0.022	0.681	<.001	6	view →
SKCM	OS	Median	III,IV	0.388	0.734	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PHF21A–BLCA (OS)

Open the BLCA breakdown →